Vaccines form an important part of the combat against the current COVID-19 health crisis. Getting a range of effective vaccines to the market quickly will be essential if we are ever to “return to normal”. Following the landmark moment of a first COVID-19 vaccine approval in December 2020, this article explores how an accelerated regulatory pathway using challenge studies could speed up time to market for further COVID-19 vaccines.
The current SARS-CoV-2 pandemic creates an unprecedented health crisis on a global scale. Pandemic diseases – epidemic diseases that spread over a wide region – are not new and have swept through human populations for millennia.
Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses (Venn Life Sciences and hVIVO) and is also developing a genomics data platform business (Genomic Health Data).